• Dr. Wei obtained his M.D. from China Medical University (Shenyang, China) and received his Ph.D. from Okayama University in Japan. He completed a post-doctoral fellowship at Washington University School of Medicine (St. Louis, Missouri) prior to coming to UAB, where he finished his pathology residency followed by a surgical pathology fellowship. He obtained additional clinical subspecialty training at Emory, Mt. Sinai and Harvard Universities. Dr. Wei is board certified in Anatomic and Clinical Pathology. He joined the faculty at UAB in July, 2008 and is currently a Tenured Professor. Dr. Wei heads the Surgical Pathology Section at the Division of Anatomic Pathology, Department of Pathology, and directs the Surgical Pathology Fellowship Program.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2020 RANKLed by the Complexity of Signaling in Breast Cancer Metastasis to the BrainClinical Breast Cancer2020
    2019 PAX8 Expression in Solitary Fibrous Tumor: A Potential Diagnostic PitfallApplied Immunohistochemistry and Molecular Morphology.  27:195-202. 2019
    2019 Loss of FOXP3 and TSC1 accelerates prostate cancer progression through synergistic transcriptional and posttranslational regulation of c-MycCancer Research.  79:1413-1425. 2019
    2018 Comparison of AJCC Anatomic and Clinical Prognostic Stage Groups in Breast Cancer: Analysis of 3322 Cases From a Single InstitutionClinical Breast Cancer.  18:e1347-e1352. 2018
    2018 The neutrophil chemoattractant peptide proline-glycine-proline is associated with acute respiratory distress syndrome 2018
    2018 Clinicopathologic Features and Clinical Outcome Differences in De Novo Versus Secondary Histiocytic Sarcomas: A Multi-institutional Experience and Review of the LiteratureClinical Lymphoma, Myeloma and Leukemia.  18:e427-e435. 2018
    2017 Not Your Typical Renal CystAmerican Journal of Medicine.  130:e429-e432. 2017
    2017 Carcinoma in situ involving sclerosing adenosis: Seeking the salient histological characteristics to prevent overdiagnosisAnnals of Clinical and Laboratory Science.  47:529-534. 2017
    2017 Soft tissue tumor immunohistochemistry update illustrative examples of diagnostic pearls to avoid pitfallsArchives of Pathology and Laboratory Medicine.  141:1072-1091. 2017
    2017 MicroRNA-200c and microRNA- 141 are regulated by a FOXP3-KAT2B axis and associated with tumor metastasis in breast cancerBreast Cancer Research.  19. 2017
    2017 Differential gene expression in ductal carcinoma in situ of the breast based on ERBB2 statusCancer Control : Journal of the Moffitt Cancer Center.  24:102-110. 2017
    2017 Metastatic organotropism: An intrinsic property of breast cancer molecular subtypesAdvances in Anatomic Pathology.  24:78-81. 2017
    2017 Reduced E-Cadherin and Aberrant β-Catenin Expression are Associated with Advanced Disease in Signet-Ring Cell CarcinomasApplied Immunohistochemistry and Molecular Morphology.  25:432-438. 2017
    2016 Papillary lesions of the breast an updateArchives of Pathology and Laboratory Medicine.  140:628-643. 2016
    2016 Silencing of CD24 enhances the PRIMA-1-induced restoration of mutant p53 in prostate cancer cellsClinical Cancer Research.  22:2545-2554. 2016
    2016 Prognostic value of E-cadherin and β-catenin in triple-negative breast cancerAmerican Journal of Clinical Pathology.  146:603-610. 2016
    2016 Protective effect of suppressing STAT3 activity in LPS-induced acute lung injury 2016
    2016 The rank pathway in advanced breast cancer: Does Src play a role?Applied Immunohistochemistry and Molecular Morphology.  24:42-50. 2016
    2015 Effect of African-American Race on Tumor Recurrence after Radical Cystectomy for Urothelial Carcinoma of the BladderClinical Genitourinary Cancer.  13:469-475. 2015
    2015 FOXP3-MIR-146-NF-κB axis and therapy for precancerous lesions in prostateCancer Research.  75:1714-1724. 2015
    2015 PARP1 and phospho-p65 protein expression is increased in human HER2-positive breast cancersBreast Cancer Research and Treatment.  150:569-579. 2015
    2015 Breast cancer subtypes predispose the site of distant metastasesAmerican Journal of Clinical Pathology.  143:471-478. 2015
    2015 GATA3 expression in advanced breast cancer: Prognostic value and organ-specific relapseAmerican Journal of Clinical Pathology.  144:756-763. 2015
    2015 The utility of phosphohistone H3 in breast cancer gradingApplied Immunohistochemistry and Molecular Morphology.  23:689-695. 2015
    2014 Breast implant-associated anaplastic large cell lymphoma: Review of a distinct clinicopathologic entityArchives of Pathology and Laboratory Medicine.  138:842-846. 2014
    2014 Characteristics of breast carcinoma cases with false-negative sentinel lymph nodesClinical Breast Cancer.  14:280-284. 2014
    2014 L-2-hydroxyglutarate: An epigenetic modifier and putative oncometabolite in renal cancerCancer Discovery.  4:1290-1298. 2014
    2014 Round cell tumors of bone: An update on recent molecular genetic advancesAdvances in Anatomic Pathology.  21:359-372. 2014
    2013 Syndecan-1 overexpression is associated with nonluminal subtypes and poor prognosis in advanced breast cancerAmerican Journal of Clinical Pathology.  140:468-474. 2013
    2013 Microsatellite instability and TARBP2 mutation study in upper urinary tract urothelial carcinomaAmerican Journal of Clinical Pathology.  139:765-770. 2013
    2013 Sclerosing epithelioid fibrosarcoma of the pancreasAnnals of Diagnostic Pathology.  17:214-216. 2013
    2012 CD138 (syndecan-1) expression in bone-forming tumorsAmerican Journal of Clinical Pathology.  137:423-428. 2012
    2011 Composite cutaneous atypical vascular lesion and Langerhans cell histiocytosis after radiation for breast carcinoma: Can radiation induce Langerhans cell histiocytosis?Dermatology Online Journal.  17. 2011
    2011 Breast carcinomas with isolated bone metastases have different hormone receptor expression profiles than those with metastases to other sites or multiple organsAnnals of Diagnostic Pathology.  15:79-83. 2011
    2009 Estrogen and progesterone receptor expression is not always specific for mammary and gynecologic carcinomas: A tissue microarray and pooled literature review studyApplied Immunohistochemistry and Molecular Morphology.  17:393-402. 2009
    2008 Sinonasal teratocarcinosarcoma: report of a case with review of literature and treatment outcomeAnnals of Diagnostic Pathology.  12:415-425. 2008
    2007 p38 MAPK as a potential therapeutic target for inflammatory osteolysisAdvances in Anatomic Pathology.  14:42-45. 2007


    Year Title Altmetric
    2015 Advances in surgical pathology: Breast cancer 2015


    Year Title Altmetric
    2015 Molecular pathology of osteosarcoma.  213-222. 2015
    2014 Benign Tumors and Tumor-Like Conditions of Bone.  838-855. 2014
    2014 MaLignant Tumors of Bone.  856-873. 2014

    Research Overview

  • Dr. Wei is actively engaged in the diagnostic surgical pathology service and has special interests in breast, muskuloskeletal and genitourinary pathology. His major research interests include discovery and evaluation of biomarkers in breast cancer and other malignancies, evaluation of prognostic factors in breast cancer and malignant bone tumors, and tumor bone metastasis. He has published more than a hundred manuscripts in these areas in some of the leading peer-reviewed journals, of which he first- or senior-authored approximately two-thirds. Dr. Wei is a Senior Scientist at UAB Comprehensive Cancer Center, Experimental Therapeutics Program. He co-directs the Pathology Research Core Laboratory.

    Keywords: Breast Pathology; Muskuloskeletal Pathology; Genitourinary Pathology
  • Investigator On

  • Identifying a New Biological Target for Breast Cancer Therapy That Contributes to Disparities for African-American Women  awarded by National Cancer Institute/NIH/DHHS 2020 - 2025
  • TBCRC -AURORA US: A Prospective Biospecimen Repository in Metastic Breast Cancer  awarded by Johns Hopkins University 2020 - 2025
  • Synergistic Targeted Therapy of Antibody-Drug Conjugates for Triple-Negative Breast Cancer  awarded by National Cancer Institute/NIH/DHHS 2020 - 2024
  • Utilizing microRNA-146a to Block Triple-Negative Breast Cancer Cell Colonization  awarded by National Cancer Institute/NIH/DHHS 2019 - 2021
  • 3/3 Morehouse School of Medicine/Tuskegee University/University of Alabama Cancer Center Partnership  awarded by National Cancer Institute/NIH/DHHS 2016 - 2021
  • Morehouse School of Medicine/Tuskegee University/University of Alabama Cancer Center Partnership: Project 1: CD24-Dependent Inactivation of Mutant p53 in Metastatic Castration-Resistant Prostate Cancer  awarded by National Cancer Institute/NIH/DHHS 2016 - 2021
  • UAB 1174: Investigation of Serial Studies to Predict your Therapeutic Response with Imaging and Molecular Analysis 2  awarded by QUANTUM LEAP HEALTH CARE 2018 - 2020
  • Effects of CD24-RCC2 Signaling on Prostate Cancer Metastasis  awarded by DOD - ARMY MEDICAL RESEARCH ACQUISITION ACTIVITY 2015 - 2020
  • UAB 1174: Investigation of Serial Studies to Predict your Therapeutic Response with Imaging and Molecular Analysis 2  awarded by QUANTUM LEAP HEALTH CARE 2012 - 2019
  • Prospective Study of MRI and Multi-Parameter Gene Expression Assay in Ductal Carcinoma in Situ (DCIS) (R15-037)  awarded by American College of Radiology Imaging Network 2015 - 2017
  • Whole Exome and Comprehensive Kinomics Analysis of Penile Squamous Cell Carcinoma  awarded by Conquer Cancer Foundation of ASCO 2014 - 2015
  • Whole Exome Sequencing of Penile Squamous Cell Carcinoma to Improve Prognostication and Uncover Potentially Actionable Therapeutic Targets  awarded by FONDAZIONE IRCCS INSITUTO NAZIONLE DEI TUMORI 2014 - 2015
  • Elevated NF-kB Signaling in Breast Cancers of African American Women  awarded by H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE 2013
  • Education And Training

  • Doctor of Medicine, China Medical University 1989
  • UAB Hospital, Residency 2008
  • Full Name

  • Shi Wei